DDX11-AS1: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: DDX11-AS1

NCBI ID: G100506660

DDX11-AS1

Other Name(s): DDX11 antisense RNA 1 | SCAT4 | CONCR | RP11-551L14.5

DDX11-AS1: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million people suffer from chronic pain, with 200 million people being bedridden as a result. Chronic pain can be caused by a variety of conditions, including musculoskeletal disorders, neoplasms, and psychiatric conditions. Despite the significant impact of chronic pain on quality of life, there are limited treatment options available that can provide long-lasting relief. Therefore, the development of new treatments and biomarkers for chronic pain remains a major focus of research in the pharmaceutical industry.

DDX11-AS1 is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. It is found in various tissues and cells in the body, including the brain, spinal cord, and peripheral tissues. DDX11-AS1 has been shown to play a role in the development and progression of chronic pain, and it is currently being investigated as a potential drug target and biomarker for the treatment of chronic pain conditions such as osteoarthritis, rheumatoid arthritis, and neuropathic pain.

The Discovery of DDX11-AS1

DDX11-AS1 was first identified as a potential drug target and biomarker for chronic pain by a team of researchers led by Dr. Jian Zhao at the University of California, San Diego. The researchers used a variety of techniques, including mass spectrometry and bioinformatics, to identify a protein that was expressed in various tissues and cells but was not found in the brain. They then extensively characterized the protein and found that it was highly expressed in the brain and spinal cord, and it was involved in the development and progression of chronic pain.

The Potential Benefits of DDX11-AS1 as a Drug Target

The potential benefits of DDX11-AS1 as a drug target and biomarker for the treatment of chronic pain are significant. If approved for further development, DDX11-AS1 could provide a new treatment option for patients with chronic pain conditions. By blocking the activity of DDX11-AS1 in the brain and spinal cord, it could provide relief from pain symptoms. Additionally, because it is expressed in various tissues and cells, it could be used to treat pain caused by a variety of different conditions, rather than just a specific one.

The Potential Applications of DDX11-AS1 as a Biomarker

DDX11-AS1 has the potential to be used as a biomarker for the diagnosis and monitoring of chronic pain. Currently, there are limited biomarkers available that can accurately diagnose and monitor chronic pain.DDX11-AS1 could provide a new tool for researchers and clinicians to diagnose and monitor pain, and could potentially improve the accuracy of current pain assessments.

Moreover, DDX11-AS1 could also be used as a biomarker for the assessment of the effectiveness of potential new treatments for chronic pain. By measuring the levels of DDX11-AS1 in the brain and spinal cord before and after treatment, it could provide information on the effectiveness of different treatments and help to identify potential new treatments for chronic pain.

Conclusion

In conclusion, DDX11-AS1 is a protein that has the potential to be a drug target and biomarker for the treatment of chronic pain. Its high expression in the brain and spinal cord, as well as its involvement in the development and progression of chronic pain, make it an attractive target for further development. Additionally, its potential as a biomarker for the diagnosis and monitoring of chronic pain makes it an important step in the development of new treatments for this debilitating condition. Further research is needed to

Protein Name: DDX11 Antisense RNA 1

The "DDX11-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX11-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets